Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1- (β-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 1274-1277

  Song, Xueqin ^a   Vig, Balvinder S ^a   Lorenzi, Philip L ^a   Drach, John C ^a   Townsend, Leroy B ^b   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO 5,6 DICHLORO 1 (BETA DEXTRO RIBOFURANOSYL)BENZIMIDAZOLE; AMINO ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; GLYCINE; GLYCYLSARCOSINE; OLIGOPEPTIDE; PEPTIDE TRANSPORTER 1; PRODRUG; SERINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; DRUG SYNTHESIS; HELA CELL; HYDROPHOBICITY; IC 50;

NON-PROGRAMMATIC;

AMINO ACIDS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DIPEPTIDES; ESTERS; HELA CELLS; HUMANS; PRODRUGS; RIBONUCLEOSIDES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SYMPORTERS;

EID: 13944252830     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049450i     Document Type: Article

References (32)

1. Hayden, F. G. Antiviral agents, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; McGraw-Hill: New York, 2001; pp 1313-1347.
2. De Clercq, E. Antiviral Drugs: Current State of the Art. J. Clin. Virol. 2001, 22, 73-89.
3. Kennedy, T. Managing the Drug discovery/Development Interface. Drug Discuss. Today 1997, 2, 436-444.
4. Thummel, K. E.; Shen, D. A. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; McGraw-Hill: New York, 2001; pp 1917-2023.
5. Fleisher, D.; Bong, R.; Stewart, B. H. Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs. Adv. Drug Delivery Rev. 1886, 19, 115-130.
6. Han, H. K.; Amidon, G. L. Targeted Prodrug Design to Optimize Drug Delivery. AAPS Pharmsci. 2000, 2, E6.
7. Oh, D. M.; Han, H. K.; Amidon, G. L. Drug Transport and Targeting. Intestinal Transport. Membrane Transporters as Drug Targets; Kluwer Academic/Plenum: New York, 1999; pp 59-88.
8. Balimane, P. V.; Tamai, I.; Guo, A.; Nakanishi, T.; Kitada, H. Leibach, F. H.; Tsuji, A.; Sinko, P. J. Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Non-peptide Prodrug, Valacyclovir. Biochem. Biophys. Res. Commun. 1998, 250, 246-251.
9. Han, H.; de Vrueh, R. L.; Rhie, J. K.; Covitz, K. M.; Smith, P. L.; Lee, C. P.; Oh, D.; Sadee, W.; Amidon, G. L. 5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT are Absorbed by the Intestinal PEPT1 Peptide Transporter. Pharm. Res. 1998, 15, 1154-1159.
10. Sugawara, M.; Huang, W.; Fei, Y. L.; Leibach, F. H.; Ganapathy, V.; Ganapathy, M. E. Transport of Valganciclovir, a Ganciclovir Prodrug, via Peptide Transporters PEPT1 and PEPT2. J. Pharm. Sci. 2000, 89, 781-789.
11. Shin, H.-C.; Landowski, C. P.; Amidon, G. L. Transporters in the GI tract. In Drug Bioavailability /Estimation of Solubility, Permeability and Absorption; Waterbeemd, V.-d., Lennernas, H., Artursson, P., Eds.; Wiley-VCH: Germany, 2003.
12. Rubio-Aliaga, I.; Daniel, H. Mammalian Peptide Transporters as Targets for Drug Delivery. Trends Pharmacol. Sci. 2002, 23, 434-440.
13. Nielsen, C. U.; Brodin, B.; Jorgensen, F. S.; Frokjaer, S.; Steffansen, B. Human Peptide Transporters: Therapeutic Applications. Exp. Opin. Ther. Pat. 2002, 12, 1329-1350.
14. Inui, K.; Terada, T. Dipeptide Transporters. Pharm. Biotechnol. 1999, 12, 269-288.
15. Meredith, D.; Boyd, C. A. Structure and Function of Eukaryotic Peptide Transporters. Cell Mol. Life Sci. 2000, 57, 754-778.
16. Herrera-Ruiz, D.; Knipp, G. T. Current Perspectives on Established and Putative Mammalian Oligopeptide Transporters. J. Pharm. Sci. 2003, 92, 691-714.
17. Meier, C. Pronucleotides: recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates. Synth. Lett. 1998, 233-242.
18. Wagner, C. R.; Iyer, V. V.; McIntee, E. J. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 2000, 20, 417-451.
19. Tobias, D. C.; Borch, R. F. Synthesis and Biological Evaluation of a Cytarabine Phosphoramidate Prodrug. Mol. Pharm. 2004, 2, 112-116.
20. Townsend, L. B.; Devivar, R. V.; Turk, S. R.; Nassiri, M. R.; Drach, J. C. Design, Synthesis, and Antiviral Activity of Certain 2,5,6-trihalo-1-(β- D-ribofuranosyl)benzimidazoles. J. Med. Chem. 1995, 38, 4098-4105.
21. Zou, R.; Drach, J. C.; Townsend, L. B. Design, Synthesis, and Antiviral Evaluation of 2-chloro-5,6-dihalo-1-(β-D-ribofuranosyl)-benzimidazoles as Potential Agents for Human Cytomegalovirus Infections. J. Med. Chem. 1997, 40, 811-818.
22. Underwood, M. R.; Harvey, R. J.; Stanat, S. C.; Hemphill, M. L.; Miller, T. Drach, J. C.; Townsend, L. B.; Biron, K. K. Inhibition of Human Cytomegalovirus DNA Maturation by a Benzimidazole Ribonucleoside is Mediated Through the UL89 Gene Product. J. Virol. 1998, 72, 717-725.
23. Good, S. S.; Owens, B. S.; Townsend, L. B.; Drach, J. C. The Disposition in Rats and Monkeys of 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl) benzimidazole (BDCRB) and its 2,5,6-trichloro Congener (TCRB). Presented at the 7th International Conference on Antiviral Research, Charleston, SC, Feb 27-Mar 4, 1994.
24. Chulay, J.; Biron, K.; Wang, L.; Underwood, M.; Chamberlain, S.; Frick, L.; Good, S.; Davis, M.; Harvey, R.; Townsend, L.; Drach, J.; Koszalka, G. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv. Exp. Med. Biol. 1999, 458, 129-134.
25. Lalezari, J. P.; Aberg, J. A.; Wang, L. H.; Wire, M. B.; Richard Miner, R.; Snowden, W.; Talarico, C. L.; Shaw, S.; Jacobson, M. A.; Drew, W. L. Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding. Antimicrob. Chemotherap. 2002, 46, 2969-2976.
26. Vig, B. S.; Landowski, C. P.; Faria, T. N.; Amidon, G. L. Novel Amino Acid Ester Prodrugs of the Anticancer Agent Floxuridine as Substrates for the hPept1 Transporter: Aliphatic and Aromatic Amino Acids. Presented at the American Association of Pharmaceutical Scientists Annual Meeting & Exposition, Salt Lake City, UT, Oct 26-30, 2003.
27. Faria, T. N.; Timoszyk, J. K.; Stouch, T. R.; Vig, B. S.; Landowski, C. P.; Amidon, G. L.; Weaver, C. D.; Wall, D. A.; Smith, R. L. A Novel High Throughput PepTl Transporter Assay Differentiates Between Substrates and Antagonists. Mol. Pharm. 2003, 1, 67-76.
28. Tateoka, R.; Abe, H.; Miyauchi, S.; Shuto, S.; Matsuda, A.; Kobayashi, M.; Miyazaki, K.; Kamo, N. Significance of Substrate Hydrophobicity for Recognition by an Oligopeptide Transporter (PEPT1). Bioconjugate Chem. 2001, 12, 485-492.
29. Tamura, K.; Lee, C. P.; Smith, P. L.; Borchardt, R. T. Metabolism, Uptake, and Transepithelial Transport of the Stereoisomers of Val-Val-Val in the Human Intestinal Cell Line, Caco-2. Pharm. Res. 1996, 13, 1663-1667.
30. Tamura, K.; Bhatnagar, P. K.; Takata, J. S.; Lee, C. P.; Smith, P. L.; Borchardt, R. T. Metabolism, Uptake, and Transepithelial Transport of the Diastereomers of Val-Val in the Human Intestinal Cell Line, Caco-2. Pharm. Res. 1996, 13, 1213.
31. Sun, D.; Landowski, C. P.; Chu, X.; Wallsten, R.; Komorowski, T. E.; Fleisher, D.; Amidon, G. L. Drug Inhibition of Gly-Sar Uptake and hPepT1 Localization Using hPepT1-GFP Fusion Protein. AAPS Pharm Sci. 2001, 3, E2.
32. Hsu, C. P.; Hilfinger, J. M.; Walter, E.; Merkle, H. P.; Roessler, B. J.; Amidon, G. L. Overexpression of Human Intestinal Oligopeptide Transporter in Mammalian Cells via Adenoviral Transduction. Pharm. Res. 1998, 15, 1376-1381.